Quartalsergebnisse (Earnings) für CRISPR Therapeutics

defenseworld.net2026-08-13 03:38:57

Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP

Bank of America Corp DE lowered its position in shares of CRISPR Therapeutics AG (NASDAQ: CRSP) by 10.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 983,072 shares of the company's stock after selling 113,815 shares during the period. Bank of America

globenewswire.com2026-08-10 16:07:30

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.

seekingalpha.com2026-08-05 10:09:04

CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310

CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.

zacks.com2026-08-04 12:00:48

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.

zacks.com2026-08-03 19:46:21

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago.

globenewswire.com2026-08-03 16:15:00

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.

zacks.com2026-07-30 18:50:17

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.

fool.com2026-07-30 17:38:00

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon.

fool.com2026-07-30 16:30:00

3 Stocks With the Most Upside by the End of 2026

Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.

zacks.com2026-07-28 10:01:24

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

EPS (USD)

Umsatz (USD)

Revisionen der Gewinnschätzungen